Formulation and In-vitro Characterisation Of Fulvestrant Loaded Liposomes for Breast Cancer Therapy
Date
2017
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Department of Pharmaceutics and Pharm.Microbiology Usmanu Danfodiyo University, Sokoto
Abstract
Introduction; Materials and Methods; Results and Discussion; References
Description
One in every five cancer patients suffers from breast cancer worldwide. Also there are more than 2 million new cases reported annually, (Malik et al., 2012). Breast cancer is the second leading cause of cancer death for women in the United States. Approximately 40,290 women and 440 men are estimated to die from the disease annually, (Ellis et al., 2000). Breastcancer is estrogen-dependent, reducing estrogen secretion by oophorectomy, hypophysectomy, or adrenalectomy may lead to regression of breast cancer, (Bhatial et al., 2004).
The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnology strategies for more effective and safer cancer treatment, one of which is liposomes. Considerable technological success has been achieved in this field, but the main obstacles to nanomedicine becoming a new paradigm in cancer therapy stem from the complexities and heterogeneity of tumour biology, an incomplete understanding of nano–bio interactions and the challenges regarding chemistry, manufacturing and controls required for clinical translation and commercialization.
The outcome of this investigation proposes a novel formulation of Fulvestrant liposomes prepared by lipid film hydration technique. The liposomal particles in a nano-size range with a desired drug polymer ratio were produced. The size, drug loading and the drug release kinetics can be optimally controlled.